Checkpoint-blocked T cells checkmate AML.
作者信息
Williams Kirsten M
机构信息
Emory University.
出版信息
Blood. 2021 Jun 10;137(23):3155-3156. doi: 10.1182/blood.2021011497.
Abstract
摘要
相似文献
1
Checkpoint-blocked T cells checkmate AML.检查点阻断的T细胞战胜急性髓系白血病。
Blood. 2021 Jun 10;137(23):3155-3156. doi: 10.1182/blood.2021011497.
2
Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.急性髓系白血病的免疫治疗干预措施
Cancer Treat Res. 2022;183:225-254. doi: 10.1007/978-3-030-96376-7_8.
3
The progress and current status of immunotherapy in acute myeloid leukemia.急性髓系白血病免疫治疗的进展与现状
Ann Hematol. 2017 Dec;96(12):1965-1982. doi: 10.1007/s00277-017-3148-x. Epub 2017 Oct 28.
4
Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?
Leuk Lymphoma. 2017 Nov;58(11):2523-2531. doi: 10.1080/10428194.2017.1306646. Epub 2017 Mar 28.
5
Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.免疫疗法治疗急性髓细胞白血病（AML）：一种强有力的替代疗法。
Biomed Pharmacother. 2018 Jan;97:225-232. doi: 10.1016/j.biopha.2017.10.100. Epub 2017 Nov 6.
6
Acute myeloid leukaemia and the immune system: implications for immunotherapy.急性髓系白血病与免疫系统：免疫治疗的影响。
Br J Haematol. 2020 Jan;188(1):147-158. doi: 10.1111/bjh.16310. Epub 2019 Nov 29.
7
A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.一种新型的组织蛋白酶 G 衍生的 HLA-A*0201 限制性肽是急性髓系白血病的有效免疫治疗靶点。
Clin Cancer Res. 2013 Jan 1;19(1):247-57. doi: 10.1158/1078-0432.CCR-12-2753. Epub 2012 Nov 12.
8
[Reaserch Advances in Immunotherapy for Acute Myeloid Leukemia--Review].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Dec;28(6):2089-2092. doi: 10.19746/j.cnki.issn.1009-2137.2020.06.048.
9
The Role of T Cell Immunotherapy in Acute Myeloid Leukemia.T 细胞免疫疗法在急性髓系白血病中的作用。
Cells. 2021 Dec 1;10(12):3376. doi: 10.3390/cells10123376.
10
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.CD123靶向结合T细胞作为急性髓系白血病的新型免疫疗法
Mol Ther. 2016 Sep 29;24(9):1615-26. doi: 10.1038/mt.2016.116. Epub 2016 Jun 6.
引用本文的文献
1
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part II. Organ Dysfunction and Immune Reconstitution Considerations for Children with Chronic Graft-versus-Host Disease after Hematopoietic Cell Transplantation.儿科移植与细胞治疗联盟造血细胞移植后小儿慢性移植物抗宿主病生存的RESILIENT会议：第二部分。造血细胞移植后慢性移植物抗宿主病患儿的器官功能障碍与免疫重建考量
Transplant Cell Ther. 2025 Jan 22. doi: 10.1016/j.jtct.2025.01.885.
2
Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia.IFN-γ+ T 细胞中 PD-1/Tim-3 表达升高与急性髓系白血病患者预后不良相关。
Cancer Biol Ther. 2023 Dec 31;24(1):2278229. doi: 10.1080/15384047.2023.2278229. Epub 2023 Nov 14.
本文引用的文献
1
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.移植后复发髓系恶性肿瘤中 CTLA-4 阻断的分子和细胞特征。
Blood. 2021 Jun 10;137(23):3212-3217. doi: 10.1182/blood.2021010867.
2
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.一项多中心 1 期研究，评估纳武利尤单抗用于异基因移植后复发血液系统恶性肿瘤。
Blood. 2020 Jun 11;135(24):2182-2191. doi: 10.1182/blood.2019004710.
3
The Role of Antigen Spreading in the Efficacy of Immunotherapies.抗原扩散在免疫疗法中的作用。
Clin Cancer Res. 2020 Sep 1;26(17):4442-4447. doi: 10.1158/1078-0432.CCR-20-0305. Epub 2020 May 1.
4
Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia.在急性髓细胞白血病异基因干细胞移植后利用免疫系统。
Am J Hematol. 2020 May;95(5):529-547. doi: 10.1002/ajh.25750. Epub 2020 Feb 19.
5
Checkpoint inhibitors in AML: are we there yet?AML 中的检查点抑制剂：我们成功了吗？
Br J Haematol. 2020 Jan;188(1):159-167. doi: 10.1111/bjh.16358. Epub 2019 Dec 6.
6
Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges.检查点抑制剂与急性髓系白血病：前景与挑战
Expert Rev Hematol. 2018 May;11(5):373-389. doi: 10.1080/17474086.2018.1459184.
7
Ipilimumab for Patients with Relapse after Allogeneic Transplantation.伊匹单抗用于异基因移植后复发的患者。
N Engl J Med. 2016 Jul 14;375(2):143-53. doi: 10.1056/NEJMoa1601202.
8
Graft-versus-host disease versus graft-versus-leukemia.移植物抗宿主病与移植物抗白血病
Hematology Am Soc Hematol Educ Program. 2015;2015:225-30. doi: 10.1182/asheducation-2015.1.225.
9
Graft-versus-disease effect following allogeneic transplantation for acute leukaemia.急性白血病异基因移植后的移植物抗疾病效应。
Best Pract Res Clin Haematol. 2008 Sep;21(3):485-502. doi: 10.1016/j.beha.2008.07.002.
10
Graft-versus-leukemia reactions after bone marrow transplantation.骨髓移植后的移植物抗白血病反应。
Blood. 1990 Feb 1;75(3):555-62.
Zotero 插件